FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

Inclusion Criteria:

Diagnosis of diffuse large B cell lymphoma or aggressive (high-grade) B-cell lymphoma for which an autologous stem cell transplant is planned or recently completed

High risk for relapse defined as at least one of the below:

Primary induction failure (no complete or partial remission at any point after diagnosis
Initial remission duration < 12 months
Lack of complete metabolic (PET scan) response after 2-3 cycles of salvage chemotherapy
Evidence of c-myc and bcl-2 and/or bcl-6 re-arrangement (double hit or triple hit lymphoma)
Age-adjusted IPI 2-3 at relapse
Age 18 years or older at the time of signing consent.
Agrees to use adequate contraception (or evidence of sterility) for at least 12 months after the last dose of rituximab.
Agrees and signs the separate consent for up to 15 years of follow-up (Long-term Follow-up study CPRC#2020LS052)
Provides voluntary written consent prior to the performance of any research related activities.

Exclusion Criteria:

Receipt of any investigational therapy within 28 days prior to the first dose of FT596 or planned use of an investigational therapy during the first 100 days after transplant
Planned post-transplant irradiation prior to Day +100
Seropositive for HIV, active Hepatitis B or C infection with detectable viral load by PCR
Body weight <50kg
Known allergy to the following FT596 components: albumin (human) or DMSO
Unable to receive rituximab

Post-HSCT Reconfirmation of eligibility

No life-threatening medical issues (i.e. ongoing Grade 4 adverse events) where, in the opinion of the treating investigator, use of FT596 is not in the patient's best interest.
No active uncontrolled infection.

Adequate organ function post-transplant including:

alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 x ULN (Grade 2 CTCAE v5)
total bilirubin ≤1.5 x ULN (Grade 1 CTCAE v5)
serum creatinine ≤1.5 x ULN (Grade 1 CTCAE v5)
oxygen saturation ≥93% on room air
For Day 30 dosing only - CBC requirement consistent with engraftment (ANC>500, platelet>20,000 without transfusion support within previous 7 days). There are no CBC parameters for Day 7 dosing.
No requirement for systemic immunosuppressive therapy (> 5mg prednisone daily) during the FT596 dosing period.